QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors

被引：0
|
作者：
P Ghatalia
Y Je
M D Kaymakcalan
G Sonpavde
T K Choueiri
机构：
[1] University of Alabama at Birmingham (UAB),Department of Internal Medicine
[2] Kyung Hee University,Department of Food and Nutrition
[3] Dana Farber Cancer Institute and Harvard Medical School,Department of Internal Medicine
[4] Section of Medical Oncology,undefined
[5] UAB Medical Center,undefined
来源：
British Journal of Cancer | 2015年 / 112卷
关键词：
vascular endothelial growth factor receptor; tyrosine kinase inhibitors; approved; QTc interval prolongation; meta-analysis; cardiac toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：296 / 305
页数：9
相关论文
共 50 条
  • [31] A biopsy-guided analysis of diarrhea in patients treated with tyrosine kinase inhibitors of the vascular endothelial growth factor receptor
    Boers-Sonderen, Marye
    Mulder, Sasja
    Nagtegaal, Iris D.
    Derikx, Lauranne
    Wanten, Geert
    Mulders, Peter
    Van Der Graaf, Winette T. A.
    Hoentjen, Frank
    L-Van Herpen, Carla M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?
    Furuya-Kanamori, Luis
    Doi, Suhail Ar
    Onitilo, Adedayo
    Akhtar, Saghir
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (02) : 223 - 228
  • [33] Inhibition of choroidal neovascularization by blocking vascular endothelial growth factor receptor tyrosine kinase
    Kami, Junko
    Muranaka, Kimimasa
    Yanagi, Yasuo
    Obata, Ryo
    Tamaki, Yasuhiro
    Shibuya, Masabumi
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2008, 52 (02) : 91 - 98
  • [34] Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials
    Ghatalia, Pooja
    Je, Youjin
    El Mouallem, Nemer
    Nguyen, Paul L.
    Quoc-Dien Trinh
    Sonpavde, Guru
    Choueiri, Toni K.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 93 (03) : 257 - 276
  • [35] Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: Is the cause in the mucosa?
    Boers-Sonderen, Marye J.
    Mulder, Sasja F.
    Nagtegaal, Iris D.
    Derikx, Lauranne A. A. P.
    Wanten, Geert J. A.
    Mulders, Peter F. A.
    van der Graaf, Winette T. A.
    Hoentjen, Frank
    van Herpen, Carla M. L.
    ACTA ONCOLOGICA, 2016, 55 (04) : 444 - 448
  • [36] Inhibition of choroidal neovascularization by blocking vascular endothelial growth factor receptor tyrosine kinase
    Junko Kami
    Kimimasa Muranaka
    Yasuo Yanagi
    Ryo Obata
    Yasuhiro Tamaki
    Masabumi Shibuya
    Japanese Journal of Ophthalmology, 2008, 52 : 91 - 98
  • [37] Safety profile of vascular endothelial growth factor receptor tyrosine-kinase inhibitors in pediatrics: a pharmacovigilance disproportionality analysis
    Xue, Yifei
    Feng, Shuo
    Li, Guangyao
    Zhang, Chao
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [38] BIBLIOMETRIC ANALYSIS OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS ASSOCIATED WITH HYPERTENSION, 2013-2023
    Li, Jiaxin
    Ma, Jie
    Su, Quanbin
    Shi, Futian
    Yu, Jing
    JOURNAL OF HYPERTENSION, 2024, 42
  • [39] The unbinding studies of vascular endothelial growth factor receptor-2 protein tyrosine kinase type II inhibitors
    Kang, Cong-min
    Liu, Dong-qing
    Wang, Xin-ying
    Yu, Ri-lei
    Lv, Ying-tao
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2015, 59 : 130 - 135
  • [40] Epidermal growth factor receptor tyrosine kinase inhibitors
    Wakeling, AE
    CURRENT OPINION IN PHARMACOLOGY, 2002, 2 (04) : 382 - 387
12345